Literature DB >> 24122044

Cost-effectiveness of a package of interventions for expedited antiretroviral therapy initiation during pregnancy in Cape Town, South Africa.

Rose Zulliger, Samantha Black, David R Holtgrave, Andrea L Ciaranello, Linda-Gail Bekker, Landon Myer.   

Abstract

Initiating antiretroviral therapy (ART) early in pregnancy is an important component of effective interventions to prevent the mother-to-child transmission of HIV (PMTCT). The rapid initiation of ART in pregnancy(RAP) program was a package of interventions to expedite ART initiation in pregnant women in Cape Town, South Africa. Retrospective cost-effectiveness, sensitivity and threshold analyses were conducted of the RAP program to determine the cost-utility thresholds for rapid initiation of ART in pregnancy. Costs were drawn from a detailed micro-costing of the program. The overall programmatic cost was US$880 per woman and the base case cost-effectiveness ratio was US$1,160 per quality-adjusted lifeyear (QALY) saved. In threshold analyses, the RAP program remained cost-effective if mother-to-child transmission was reduced by C0.33 %; if C1.76 QALY were saved with each averted perinatal infection; or if RAP-related costs were under US$4,020 per woman. The package of rapid initiation services was very cost-effective, as compared to standard services in this setting. Threshold analyses demonstrated that the intervention required minimal reductions in perinatal infections in order to be cost-effective. Interventions for the rapid initiation of ART in pregnancy hold considerable potential as a cost-effective use of limited resources for PMTCT in sub-Saharan Africa.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24122044      PMCID: PMC3984926          DOI: 10.1007/s10461-013-0641-7

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  25 in total

1.  Cost-effectiveness of using HAART in prevention of mother-to-child transmission in the DREAM-Project Malawi.

Authors:  Stefano Orlando; Maria Cristina Marazzi; Sandro Mancinelli; Giuseppe Liotta; Susanna Ceffa; Pietro Giglio; Ellard Alumando; Isabelle Ziegler; Mary Shawa; Leonardo Palombi
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

2.  Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings.

Authors:  Sada Soorapanth; Stephanie Sansom; Marc Bulterys; Mitchell Besser; Gerhard Theron; Mary Glenn Fowler
Journal:  J Acquir Immune Defic Syndr       Date:  2006-06       Impact factor: 3.731

3.  A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission.

Authors:  Taha E Taha; Elizabeth R Brown; Irving F Hoffman; Wafaie Fawzi; Jennifer S Read; Moses Sinkala; Francis E A Martinson; George Kafulafula; Gernard Msamanga; Lynda Emel; Samuel Adeniyi-Jones; Robert Goldenberg
Journal:  AIDS       Date:  2006-06-12       Impact factor: 4.177

Review 4.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

Review 5.  Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Authors:  Nandi Siegfried; Lize van der Merwe; Peter Brocklehurst; Tin Tin Sint
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

6.  Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Authors:  L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

7.  Pilot programme for the rapid initiation of antiretroviral therapy in pregnancy in Cape Town, South Africa.

Authors:  Landon Myer; Rose Zulliger; Samantha Black; David Pienaar; Linda-Gail Bekker
Journal:  AIDS Care       Date:  2012-04-23

8.  Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.

Authors:  Elisa F Long; Robert R Stavert
Journal:  J Gen Intern Med       Date:  2013-04-16       Impact factor: 5.128

9.  Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa.

Authors:  Vivian Black; Risa M Hoffman; Catherine A Sugar; Priya Menon; Francois Venter; Judith S Currier; Helen Rees
Journal:  J Acquir Immune Defic Syndr       Date:  2008-11-01       Impact factor: 3.731

10.  Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa.

Authors:  Felicity C Fitzgerald; Linda-Gail Bekker; Richard Kaplan; Landon Myer; Stephen D Lawn; Robin Wood
Journal:  S Afr Med J       Date:  2010-12-01
View more
  11 in total

1.  Evolution of antiretroviral therapy services for HIV-infected pregnant women in Cape Town, South Africa.

Authors:  Landon Myer; Tamsin Phillips; Victoria Manuelli; James McIntyre; Linda-Gail Bekker; Elaine J Abrams
Journal:  J Acquir Immune Defic Syndr       Date:  2015-02-26       Impact factor: 3.731

2.  Cost-effectiveness analysis of the prevention of mother-to-child transmission of HIV.

Authors:  Shui-Ling Qu; Ai-Ling Wang; Hong-Mei Yin; Jin-Qi Deng; Xiao-Yan Wang; Ye-Huan Yang; Xiao-Ping Pan; Tong Zhang
Journal:  Infect Dis Poverty       Date:  2022-06-15       Impact factor: 10.485

3.  Comparing the cost effectiveness of harm reduction strategies: a case study of the Ukraine.

Authors:  Sung Wook Kim; Anni-Maria Pulkki-Brannstrom; Jolene Skordis-Worrall
Journal:  Cost Eff Resour Alloc       Date:  2014-11-24

4.  Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.

Authors:  Naoko Ishikawa; Takuro Shimbo; Shinsuke Miyano; Izukanji Sikazwe; Albert Mwango; Massimo N Ghidinelli; Gardner Syakantu
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

5.  Costs and economies of scale in the accelerated program for prevention of mother-to-child transmission of HIV in Zimbabwe.

Authors:  I Ochoa-Moreno; S Bautista-Arredondo; S I McCoy; R Buzdugan; C Mangenah; N S Padian; F M Cowan
Journal:  PLoS One       Date:  2020-05-20       Impact factor: 3.240

6.  Cost-effectiveness of HIV Prevention Interventions in Sub-Saharan Africa: A Systematic Review.

Authors:  Supriya Sarkar; Phaedra Corso; Shideh Ebrahim-Zadeh; Patricia Kim; Sana Charania; Kristin Wall
Journal:  EClinicalMedicine       Date:  2019-05-20

7.  Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa.

Authors:  Caitlin M Dugdale; Tamsin K Phillips; Landon Myer; Emily P Hyle; Kirsty Brittain; Kenneth A Freedberg; Lucy Cunnama; Rochelle P Walensky; Allison Zerbe; Milton C Weinstein; Elaine J Abrams; Andrea L Ciaranello
Journal:  PLoS One       Date:  2019-11-15       Impact factor: 3.240

8.  The short-term effects of the implementation of the "Treat All" guidelines on ART service delivery costs in Namibia.

Authors:  Carl Schutte; Steven Forsythe; Johnface Fedes Mdala; Brady Zieman; Rachael Linder; Lung Vu
Journal:  PLoS One       Date:  2020-01-27       Impact factor: 3.240

9.  Costs along the service cascades for HIV testing and counselling and prevention of mother-to-child transmission.

Authors:  Sergio Bautista-Arredondo; Sandra G Sosa-Rubí; Marjorie Opuni; David Contreras-Loya; Ada Kwan; Claire Chaumont; Abson Chompolola; Jeanine Condo; Omar Galárraga; Neil Martinson; Felix Masiye; Sabin Nsanzimana; Ivan Ochoa-Moreno; Richard Wamai; Joseph Wang'ombe
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

10.  Benefits and risks of rapid initiation of antiretroviral therapy.

Authors:  Nathan Ford; Chantal Migone; Alexandra Calmy; Bernhard Kerschberger; Steve Kanters; Sabin Nsanzimana; Edward J Mills; Graeme Meintjes; Marco Vitoria; Meg Doherty; Zara Shubber
Journal:  AIDS       Date:  2018-01-02       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.